Publications

Kuszak AJ, Espey MGraham, Falk MJ, Holmbeck MA, Manfredi G, Shadel GS, Vernon HJ, Zolkipli-Cunningham Z.  2017.  Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.. Annu Rev Pathol.

Kummer BR, Gialdini G, Sevush JL, Kamel H, Patsalides A, Navi BB.  2016.  External Validation of the Cincinnati Prehospital Stroke Severity Scale.. J Stroke Cerebrovasc Dis. 25(5):1270-1274.

Kummer BR, Bhave PD, Merkler AE, Gialdini G, Okin PM, Kamel H.  2015.  Demographic Differences in Catheter Ablation After Hospital Presentation With Symptomatic Atrial Fibrillation.. J Am Heart Assoc. 4(9):e002097.

Kummer BR, Lerario MP, Navi BB, Ganzman AC, Ribaudo D, Mir SA, Pishanidar S, Lekic T, Williams O, Kamel H et al..  2018.  Clinical Information Systems Integration in New York City's First Mobile Stroke Unit.. Appl Clin Inform. 9(1):89-98.

Kuceyeski A, Monohan E, Morris E, Fujimoto K, Vargas W, Gauthier SA.  2018.  Baseline biomarkers of connectome disruption and atrophy predict future processing speed in early multiple sclerosis.. Neuroimage Clin. 19:417-424.

Kuceyeski A, Navi BB, Kamel H, Raj A, Relkin N, Toglia J, Iadecola C, O'Dell M.  2016.  Structural connectome disruption at baseline predicts 6-months post-stroke outcome.. Hum Brain Mapp. 37(7):2587-601.

Krusche P, Trigg L, Boutros PC, Mason CE, De La Vega FM, Moore BL, Gonzalez-Porta M, Eberle MA, Tezak Z, Lababidi S et al..  2019.  Best practices for benchmarking germline small-variant calls in human genomes.. Nat Biotechnol.

Krusche P, Trigg L, Boutros PC, Mason CE, De La Vega FM, Moore BL, Gonzalez-Porta M, Eberle MA, Tezak Z, Lababidi S et al..  2019.  Author Correction: Best practices for benchmarking germline small-variant calls in human genomes.. Nat Biotechnol.

Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, Ravits JM, Miller TM, Maragakis NJ, Hales CM et al..  2017.  Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients.. Mol Neurodegener. 12(1):76.

Koizumi K, Wang G, Park L.  2016.  Endothelial Dysfunction and Amyloid-β-Induced Neurovascular Alterations.. Cell Mol Neurobiol. 36(2):155-65.

Koizumi K, Hattori Y, Ahn SJi, Buendia I, Ciacciarelli A, Uekawa K, Wang G, Hiller A, Zhao L, Voss HU et al..  2018.  Apoε4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function.. Nat Commun. 9(1):3816.

Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.

Kobayashi M, Benakis C, Anderson C, Moore MJ, Poon C, Uekawa K, Dyke JP, Fak JJ, Mele A, Park CY et al..  2019.  AGO CLIP Reveals an Activated Network for Acute Regulation of Brain Glutamate Homeostasis in Ischemic Stroke.. Cell Rep. 28(4):979-991.e6.

Kim E, Cho S.  2016.  Microglia and Monocyte-Derived Macrophages in Stroke.. Neurotherapeutics. 13(4):702-718.

Kim E, Yang J, Park KWoo, Cho S.  2017.  Inhibition of VEGF Signaling Reduces Diabetes-Exacerbated Brain Swelling, but Not Infarct Size, in Large Cerebral Infarction in Mice.. Transl Stroke Res.

Kim E, Woo M-S, Qin L, Ma T, Beltran CD, Bao Y, Bailey JA, Corbett D, Ratan RR, Lahiri DK et al..  2015.  Daidzein Augments Cholesterol Homeostasis via ApoE to Promote Functional Recovery in Chronic Stroke.. J Neurosci. 35(45):15113-26.

Kim S-E, Lei Y, Hwang S-H, Wlodarczyk BJ, Mukhopadhyay S, Shaw GM, M Ross E, Finnell RH.  2018.  Dominant negative GPR161 rare variants are risk factors of human spina bifida.. Hum Mol Genet.

Khormaee S, Do HT, Mayr Y, Gialdini G, Kamel H, Lyman S, Cross MB.  2018.  Risk of Ischemic Stroke After Perioperative Atrial Fibrillation in Total Knee and Hip Arthroplasty Patients.. J Arthroplasty.

Kenny TC, Manfredi G, Germain D.  2017.  The Mitochondrial Unfolded Protein Response as a Non-Oncogene Addiction to Support Adaptation to Stress during Transformation in Cancer and Beyond.. Front Oncol. 7:159.

Kawamata H, Manfredi G.  2017.  Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases.. J Cell Biol. 216(12):3917-3929.

Kawamata H, Peixoto P, Konrad C, Palomo G, Bredvik K, Gerges M, Valsecchi F, Petrucelli L, Ravits JM, Starkov A et al..  2017.  Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo.. Mol Neurodegener. 12(1):37.

Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T, Perumal JS.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.

Kamel H, Merkler AE, Iadecola C, Gupta A, Navi BB.  2019.  Tailoring the Approach to Embolic Stroke of Undetermined Source: A Review.. JAMA Neurol.

Kamel H, Gialdini G, Baradaran H, Giambrone AE, Navi BB, Lerario MP, Min JK, Iadecola C, Gupta A.  2017.  Cryptogenic Stroke and Nonstenosing Intracranial Calcified Atherosclerosis.. J Stroke Cerebrovasc Dis. 26(4):863-870.